Click image to enlargeEffects of ziltivekimab versus placebo on cardiovascular outocomes in participants with established atheroscleotic cardiovascular disease, chronic kidney disease, systemic inflammation.
Criteria:Patients above the age of 18 years of age.
eGFR >15 and <60 mL/min.
Serum c-reactive protein of >2 mg/L
Established atherosclerotic cardiovascular disease.